#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Ehlers-Danlos syndrome Becker's muscular dystrophy Hodgkin's disease Vernal keratoconjunctivitis Pouchitis Anti-myelin-associated glycoprotein antibodies positive Vascular malformation Chondrosarcoma metastatic Chronic lymphocytic leukaemia refractory Immunodeficiency congenital Leber's congenital amaurosis Congenital myopathy Sjogren's syndrome Autoinflammation with infantile enterocolitis Trigeminal neuralgia More trials…

    Learn about Rare Diseases

    Angiosarcoma non-metastatic – Life with Disease Chondrosarcoma – Treatment Skin angiosarcoma – Trials in Disease Ocular melanoma – Life with Disease Isodicentric chromosome 15 syndrome Haemophagocytic lymphohistiocytosis – Life with Disease Immunodeficiency congenital – Trials in Disease Congenital nephrogenic diabetes insipidus – Trials in Disease Usher’s syndrome – Life with Disease Breast angiosarcoma metastatic – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Gadoxetic Acid, Disodium Flutemetamol (18F) Lymecycline Lithium Sulphate, Anhydrous Balcinrenone SOFTISAN 378 Gilteritinib Human Coagulation Factor Vii Urapidil AP31969 SULFATE CHONDROITIN SULFATE SODIUM Xenon (129Xe) Bms-986408 Betula Verrucosa (108) Nemtabrutinib Sxr1096 Alemtuzumab Tetracaine Hydrochloride Lutikizumab Barzolvolimab More therapies…

    Learn about Your Condition

    Haemofiltration Double hit lymphoma Cardiac disorder Erythema multiforme Oesophageal achalasia Cutaneous sarcoidosis Thromboembolectomy Lennox-Gastaut syndrome Post procedural swelling Hypertrophic scar Substance use disorder Neurodevelopmental disorder Acromegaly Cervix carcinoma stage III Crohn's disease More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Institut Regional Du Cancer De Montpellier

Institut Regional Du Cancer De Montpellier

208 Avenue Des Apothicaires, Montpellier, 34298, France

Want to learn more about this study or check if you can participate? Contact us.

  • Study Comparing Chemotherapy Alone to Chemotherapy with Nivolumab or Nivolumab and BMS-986205 for Patients with Muscle-Invasive Bladder Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Bladder cancer
    Investigated Drugs:
    • Cisplatin
    • Gemcitabine Hydrochloride
    • Nivolumab
    Austria Belgium Finland France Germany Greece +5

  • Study of palbociclib with hormone therapy guided by ESR1 mutation monitoring in patients with ER-positive, HER2-negative metastatic breast cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Anastrozole
    • Exemestane
    • Fulvestrant
    France

  • Study of Disitamab Vedotin and Pembrolizumab for Patients with Untreated Advanced Urothelial Cancer Expressing HER2

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Disitamab Vedotin
    • Carboplatin
    • Cisplatin
    Austria Belgium Czechia France Greece Hungary +7

  • Study on the Effectiveness of Lutetium (177Lu) Oxodotreotide and Octreotide in Patients with Advanced GEP-NET Tumors (Grade 2 and 3)

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Lutetium (177Lu) Oxodotreotide
    • L-Arginine Hydrochloride
    • L-Lysine Hydrochloride
    France Germany Italy The Netherlands Spain

  • Study of Capivasertib and Abiraterone for Patients with Metastatic Hormone-Sensitive Prostate Cancer with PTEN Deficiency

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Hormone-dependent prostate cancer
    Investigated Drugs:
    • Abiraterone Acetate
    • Capivasertib
    Belgium Bulgaria Czechia France Germany The Netherlands +3

  • Study comparing 177Lu-edotreotide versus everolimus in patients with inoperable progressive neuroendocrine tumors of gastroenteric or pancreatic origin

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Gastroenteropancreatic neuroendocrine tumour disease
    Investigated Drugs:
    • Lutetium (177Lu) Edotreotide
    • Everolimus
    • L-Arginine Hydrochloride
    Austria Belgium Czechia France Germany Italy +3

  • Study on Infertility Risk from Chemotherapy in Young Breast Cancer Patients Using Follitropin Beta and Follitropin Alfa for Egg/Embryo Preservation

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Breast cancer female
    Investigated Drugs:
    • Follitropin Alfa
    France

  • Study on the Effectiveness and Safety of Atezolizumab and Drug Combination for Patients with Metastatic Non-Small Cell Lung Cancer

    Not recruiting

    1 1 1 1
    Investigated Drugs:
    • Camonsertib
    • Linagliptin
    • Atezolizumab
    France Spain

  • Study on EO4010 Vaccine with Nivolumab and Bevacizumab for Patients with Metastatic Colorectal Cancer Who Have Already Received Treatment

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Colorectal cancer metastatic
    Investigated Drugs:
    • Eo2317
    • Eo2318
    • Omp10
    France Spain

  • Study Comparing Regorafenib and Regorafenib-Irinotecan Combination for Patients with Metastatic Colorectal Cancer After Standard Treatments Have Failed

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Colorectal cancer metastatic
    Investigated Drugs:
    • Regorafenib
    • Irinotecan
    France
Previous Page
1 … 19 20 21 22 23 … 25
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!